A Times investigation suggests that strict rules on the use of antipsychotic drugs in elder care have a gaping loophole.
The settlement comes more than a year after Karen Garner, then 73, was grabbed by a police officer and flung to the ground for allegedly shoplifting from a Walmart.
Irisin, a hormone produced by muscles during exercise, can enter the brain and improve cognition, a mouse study suggests.
The pathologies underlying brain decline can begin years before symptoms emerge. Can everyday behavior provide warning?
By studying centenarians, researchers hope to develop strategies to ward off Alzheimer’s disease and slow brain aging for all of us.
On Monday, a 17-year drought in the world of Alzheimer’s drugs ended with the FDA approval of Biogen’s Aduhlem (aducanumab). The controversy behind the FDA’s decision was considerable, but it doesn’t seem to be spooking drug developers who are now narrowing in on the degenerative brain disease.
In a nutshell, the approval of Aduhelm came after conflicting results from clinical trials. In November 2020 an independent FDA advisory board did not recommend that the agency endorse the drug, but in June, the agency approved the drug anyway via an Accelerated Approval Program.
Aduhelm is now the first novel treatment to address one underlying cause of Alzheimer’s – beta-amyloid plaques that accumulate in the brain.
The drug received support from patient and industry groups (the FDA also noted that the “need for treatment is urgent”, in a statement explaining the agency’s choice). Still, there have been a number of doctors who have expressed concern. One member of the expert committee that voted not to recommend the approval of Aduhelm back in November has resigned since the announcement.
However, the inconsistency of the science and highly public debate around the approval of Aduhelm doesn’t seem to have halted enthusiasm within the pharmaceutical industry. Rather, it may signal a new wave of additional treatments in the next few years, which will piggyback off of the approval of Aduhelm (however controversial that approval may be).
“This is great news for investors and for drug companies that are working towards new drugs,” says Alison Ward, a research scientist at the USC Schaeffer Center for Health Policy and Economics.
Historically there have been a few factors that have made the development of a drug for Alzheimer’s an uphill battle.
The first, is a 17-year history of failure to bring a drug through clinical trials. Even Biogen’s clinical trials for Aduhelm were halted in 2019 because it wasn’t clear that they would reach their clinical endpoints (effectively, the target outcomes of the trial). In fact, Aduhlem was approved based on a “surrogate endpoint,” the decline of beta-amyloid, not the primary endpoint, cognitive function.
Trials for Alzheimer’s drugs have also historically been expensive. A 2018 paper in Alzheimer’s and Dementia: Translational Research and Clinical Interventions (a journal run by the Alzheimer’s Association) estimated that the cost of developing an Alzheimer’s drug was about $5.6 billion. By comparison, the mean investment needed to bring a new drug to market is about $1.3 billion according to analysis of SEC filings for companies that applied for FDA approval between 2009 and 2018 (though the median cost was about $985 million). Older estimates have put the costs of bringing a drug to market at $2.8 billion.
For Alzheimer’s specifically, Phase 3 trials are still largely sponsored by industry, but over the past five years, trials sponsored solely by the industry have decreased. Government grants and funding via public-private partnerships have made up an increasing share of available funds.
Martin Tolar, the founder CEO of Alzheon, another company pursuing an oral treatment for Alzheimer’s (currently in a phase 3 clinical trial), says that attracting other forms of funding was a challenge.
“It was impossible to finance anything,” he says. “It was impossible to get Wall Street interested because everything was failing one after the other after the other.”
He expects this recent approval of Aduhelm to change that outlook considerably. Already, we are seeing some increased interest in companies already in phase 3 clinical trials: After the FDA announcement, shares of Eli Lilly, also running a phase 3 clinical trial, surged by 10 percent.
“I’ve had probably hundreds of discussions, of calls, from bankers, investors, collaborators, pharma, you name it,” Tolar says. “Alzheimer’s is open for business.”
With renewed interest and what appears like a pathway to approval at the FDA, the environment for the next generation of Alzheimer’s drugs seems to be ripening. Right now, there are about 130 phase 3 clinical trials on Alzheimer’s drugs that are either completed, active or recruiting.
Tolar sees the FDA decision, based on imperfect data, as a “signal of urgency” to approve new treatments that are imminent arrivals.
As Ward pointed out in a white paper on in-class drug innovation, “follow on” drugs go on to become leaders in the industry, especially if they demonstrate better safety or efficacy than the drug that was first to market. That, the paper argues, suggests drug approval may “pave the way” for more effective drugs in the future.
In the case of Alzheimer’s, it might not be one drug that dominates, even as more get approved, she notes. Rather, a cadre of new, approved drugs may go on to compliment one another.
“The way that the medical community is thinking of AD [Alzheimer’s Disease] now is that it’s likely going to be a combination of drugs or a cocktail of drugs that comes together to have true success at delaying progression,” she says.
“If we’re looking to treat AD with a cocktail of drugs, history suggests it’s individually approved drugs that come together to make those drug cocktails.”
There are still some potential pitfalls for future drugs to consider. One argument is that with an approved drug available, it may be more difficult to recruit participants in clinical trials, slowing the pace of drug discovery. In that respect, Ward argues that this will ultimately be dwarfed by patients who will now look into a potential diagnosis for Alzheimer’s now that there’s something to treat it with.
There’s also the fact that Aduhelm’s costs are high (about $56,000 for a year’s supply, the brunt of which will be borne by Medicare), and the data remains questionable. Those factors may push patients towards other drugs, even if they’re in clinical trials.
Additionally, there is the question of how well Aduhelm actually performs during the critical followup study mandated by the FDA as a condition of the drug’s approval. Whether Aduhelm can truly slow cognitive decline, as well as help address levels of beta-amyloid from the brain, remains questionable based on current data.
Still, Tolar doesn’t see the results of that study as particularly relevant because the industry will have moved on. Biogen CEO Michel Vounatsos has said it may not share results of this trial for as many as nine years, though he noted the company would try to deliver data sooner.
“There will be better drugs by then,” Tolar predicts.
Tolar’s phase 3 clinical trial just began dosing this week, and is scheduled to end by 2024.
Biogen and Esai will likely also have another drug ready for evaluation by then, as two phase 3 clinical trials for another beta-amyloid antibody treatment called lecanemab are scheduled for completion by 2024 and 2027.
The signal sent by Monday’s approval may be a pathway for future drugs, rather than an end itself. The data is imperfect, the costs high, and the controversy considerable, but the band-aid has been ripped off.
As people live longer and longer and have long-term health issues like cancer and dementia, caring for elderly relatives is becoming a huge societal and political issue. Right now this care is antiquated and run by incumbents, many of which still run off paper and Excel. We are now seeing a new wave of startups turn up to tackle this space by applying Apple’s age-old model of owning the experience end-to-end and running everything on a platform.
The latest to join this race is UK startup Lifted, which has now raised $6.2 million in a Series A funding round led by Fuel Ventures. Also participating were existing investor 1818 Venture Capital as well as new investors Novit Ventures, Perivoli Innovations, the J.B. Ugland family office, and a number of Angels. This latest funding round takes the total raised by Lifted to $11.2M.
Lifted says its UK market is increasing and claims the number of people caring for adult loved ones has risen exponentially during the pandemic, with almost 1 in 2 people supporting people outside their household.
The startup is entering a perfect storm of increasing need, unpopular care homes, and the UK Government still without a long-term plan for social care.
In contrast to a raft of agencies and freelancers, Lifted directly employs its care workforce and uses its platform to “gamify and improve the experience of carers to make them perform better in people’s lives and also to restore respect to the caring profession” with its Care Management Platform, says the company.
Lifted has also acquired the ‘Live Better With Dementia’ website and launched the Lifted Dementia Hub, an online community with a marketplace of products.
Rachael Crook co-founded Lifted with Sam Cohen. She says she was inspired to get into the sector when, at the age of 24, she had to care for her mother, who was diagnosed with dementia at age 56.
Rachael Crook, Lifted CEO sold me at an interview: “I was in that position much younger than most people. And it seemed abundantly clear to me that it was an experience that was hugely emotionally important to me, and financially expensive, was really convoluted and frustrating. It made an already really difficult time, more difficult. My mum brought me up to really fight for the underdog and I felt like the carers themselves were getting a really poor deal. And yet, it’s a huge colossal market. The care market is set to double in the next 20 years, and for the next 10 years, we will look to compete against traditional care companies. We want to transform the care experience. This is a product that is worth four and a half times your mortgage. And yet, it’s predominantly bought in a really antiquated way with paper and pen systems. It’s really hard to keep up to date with your loved ones’ care. We’re also competing against new entrants.”
She added: “In 12 months, we have tripled revenue, launched the first App in the world to offer free care advice, and cut Carer churn to half the industry average, all while maintaining exclusively 5-star reviews on Trustpilot.”
Mark Pearson, Managing Partner of Fuel Ventures said: “Rachael, Sam and their team have delivered exceptional growth in the past year. They have a unique vision of the future for care and their model is delivering clear results for both sides of the marketplace.”
Black players’ dementia claims were being measured differently from white players’. The change could prompt a reassessment of hundreds of previously denied cases.
Early studies reveal the toll that lockdowns, isolation and stress have taken on those who care for older Americans.
Even short-term exposure to polluted air may impair mental ability in the elderly. Aspirin and other NSAIDs showed some protective effects.
The younger the age at diagnosis for Type 2 diabetes, the higher the risk for Alzheimer’s disease and other forms of dementia years later.
Body-camera footage of the arrest of Karen Garner has drawn widespread outrage, as has another video that showed officers laughing at the footage.
Impulsive purchases, out-of-control spending: These behaviors can be early signs of Alzheimer’s disease or other cognitive decline.
Social medicine programs, which often encourage patients to engage with other people, can help address dementia, isolation and more.
Karen Garner, 73, of Loveland, Colo., walked out of a Walmart without paying for $13.88 worth of items. Police officers broke a bone in her arm and dislocated her shoulder, a lawsuit says.
The research, tracking thousands of people from age 50 on, suggests those who sleep six hours or less a night are more likely to develop dementia in their late 70s.
Nursing homes, one of the most restricted settings in America during the pandemic, are allowing visitors again. But opening the doors has brought new complications.
Players said the lawyer for the N.F.L. retiree class knew that race-based criteria were used to deny Black players’ dementia claims. A review of eight such rejections seems to support their argument.
For the millions of Americans living with dementia, every day during this pandemic can bring a fresh horror.
The analysis of nearly 62 million electronic medical records in the U.S. also found that Black people with dementia were at an even greater risk.
IBM researchers trained artificial intelligence to pick up hints of changes in language ahead of the onset of neurological diseases.
A woman in Colombia with a rare genetic mutation recently made the ultimate donation to science.
The actor, who died this weekend, struggled with the debilitating condition in his final months, his wife told The Daily Mail.
As community noise levels increased, so did the risk of Alzheimer’s disease and other forms of dementia.
Yes, you can help a cognitively impaired person participate in the election. But heed these two guidelines.
As seniors find themselves cut off from loved ones during the pandemic, some are turning to automated animals for company.
The Chicago Bears great was known for his effortless, slicing runs. Revealing his dementia diagnosis years after his retirement showed the toll of those dazzling performances.
The players say doctors use two scales — one for Black athletes, one for white — to determine eligibility for dementia claims.
Rates of dementia have steadily fallen over the past 25 years, a new study finds. But the disease is increasingly common in some parts of the world.
Scientists say such tests could be available in a few years, speeding research for treatments and providing a diagnosis for dementia patients who want to know if they have Alzheimer’s disease.
The president said on Fox News that he had to remember those words as part of a test that he said demonstrated his mental acuity. But the test, the Montreal Cognitive Assessment, is meant to detect signs of dementia, Alzheimer’s disease or other conditions.
Experts say one popular test that the president might have taken is by no means definitive, or even diagnostic.
Was he one of the hidden victims of the coronavirus pandemic?
For years, I have been making images of my mother as her dementia progresses. The process brings us closer.
The coronavirus outbreak was difficult to trace in the Wisconsin convent, which specializes in care for aging nuns with dementia.
In “On Vanishing,” Lynn Casteel Harper argues that society needs a better approach to understand and care for people who are suffering cognitive decline.
The police were leading an extensive search for Mr. Beard, an artist who disappeared on Long Island on March 31.
Being physically fit may sharpen the memory and lower our risk of dementia, even if we do not start exercising until we are older.
To support brain health as you age, start with the same foods that can help to keep your heart healthy.